Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 20, 2012

Poll Results Point to Personal Sequencing Platforms Entering the Clinic This Year

  • Personal sequencing platforms will enter the clinical diagnostic arena this year, a majority of voters on a recent GEN poll predict. While 56.4% of respondents anticipate that sequencing instrument companies will continue to develop more user-friendly and cheaper technology, focused on the benchtop and clinical markets, 35.9% do not believe success will be seen this year and 7.7% undecided.

    Research, discovery, and development applications still comprise the largest sequencing markets, but the largest market opportunity by far is in personal genomics and clinical diagnostics. Those segments are expected to reach $541 million by 2015 from $15.5 million in 2010. Recent advancements in next-generation sequencing have resulted in the advent of so-called personal genome machines. However, companies aiming at the clinical space will need to gain regulatory approval for their use in clinical laboratory diagnostics.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »